Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

34.17
-0.6800-1.95%
Post-market: 34.13-0.0379-0.11%19:57 EDT
Volume:1.79M
Turnover:61.89M
Market Cap:6.49B
PE:-9.67
High:35.60
Open:35.43
Low:34.15
Close:34.85
Loading ...

US FDA approves BridgeBio's drug for rare heart condition

Reuters
·
23 Nov 2024

BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients

Reuters
·
23 Nov 2024

Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement

THOMSON REUTERS
·
23 Nov 2024

BridgeBio Pharma trading halted, news pending

TIPRANKS
·
23 Nov 2024

BridgeBio Pharma call volume above normal and directionally bullish

TIPRANKS
·
22 Nov 2024

J.P. Morgan Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

BridgeBio Pharma Inc : JP Morgan Cuts Target Price to $40 From $43

THOMSON REUTERS
·
20 Nov 2024

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Benzinga
·
20 Nov 2024

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Simply Wall St.
·
19 Nov 2024

Stock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints

Stock Track
·
19 Nov 2024

BRIEF-Bridgebio Pharma Says Acoramidis Well Tolerated With No New Safety Signals In Long-Term Evaluation

Reuters
·
19 Nov 2024

BridgeBio reports open-label extension data on acoramidis in ATTR-CM

TIPRANKS
·
19 Nov 2024

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

THOMSON REUTERS
·
19 Nov 2024

BridgeBio Pharma Inc - Acoramidis Well Tolerated With No New Safety Signals in Long-Term Evaluation

THOMSON REUTERS
·
19 Nov 2024

BridgeBio announces publication of PROPEL 2 data in NEJM

TIPRANKS
·
18 Nov 2024

BridgeBio price target raised to $45 from $44 at Scotiabank

TIPRANKS
·
15 Nov 2024